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A virus pseudotyped with glycoprotein of vesicular stomatitis virus (VSV-G) can enter various cell types at a relatively high titer. We observed
that the amount of viral antigen from VSV-G pseudotyped human immunodeficiency virus type 1 (HIV-1) producing cells was much higher than
that from their non-pseudotyped counterparts. This enhanced viral antigen production was not observed when we used HIV-1 pol mutant, viral
enzyme inhibitors, HIV Env protein, or VSV-G fusion defective mutants. The transfection experiment using GFP-expressing virus showed time-
dependent expansion of GFP-positive cells and viral DNA integration. These results suggested that the increase in viral antigen yield was caused
by the release of a progeny virus following retro-transduction by the pseudotyped virus of the cells within the transfected cell culture. The
infectivity as well as the amount of VSV-G on virus particles per unit of viral antigen was significantly different before and after the onset of the
yield enhancement. This suggests that results of infection assays of the virus pseudotyped with VSV-G may be affected by the occurrence of such
enhancement. This means that, while pseudotyping with VSV-G is a simple and effective method, this procedure should be carefully considered
when the virus is produced for infectivity assays.
© 2007 Elsevier Inc. All rights reserved.Keywords: VSV-G; HIV-1; Pseudotyping; Viral vector; Retro-transductionIntroduction
Gene delivery using retroviral vectors has become a very
popular and indispensable method. To ensure safety of the
vectors and to increase their efficiency, envelope pseudotyping
of viral vectors lacking their own envelope gene is used in
almost all cases. Glycoprotein of vesicular stomatitis virus
(VSV-G) in particular is one of the most frequently used
envelope proteins for pseudotyping since it is very stable and
promises highly effective and broad-spectrum gene delivery.
However, there seems to be very little awareness of its adverse
effect, that is, re-infection/retro-transduction. VSV-G interacts
with a phospholipid component of the cell surface membrane
and mediates viral entry by membrane fusion (Burns et al.,
1993; Mastromarino et al., 1987). As viral entry does not seem
to require specific protein receptors, VSV-G pseudotyped⁎ Corresponding author. Fax: +81 6 6879 8347.
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doi:10.1016/j.virol.2006.12.030vectors could infect virtually all kinds of cells. Thus, the VSV-
G pseudotyped viral vector has the potential to infect its
producer cells to re-generate progenies, which may contain
unexpected characteristics. In the study presented here, we
examined retro-transduction of VSV-G pseudotyped HIV-1
vectors. Our findings suggest that this problem could
confound the interpretation of the experimental results under
certain conditions and must therefore be taken into careful
consideration.
Results
Enhancement of virion production by VSV-G pseudotyping
We previously noticed that the viral antigen yield of VSV-G
pseudotyped HIV-1 by transfection was always much higher
than that of the non-pseudotyped virus. We first reconfirmed
this phenomenon by using a simplified experimental design. For
this purpose, 2.5 μg of HIV-1 proviral plasmid pNLNh, which
lacks Env expression, was transfected into 3×106 293T cells
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G under the CAG hybrid promoter (Niwa et al., 1991), or
pGEM-5Zf(+) (Promega, Madison, WI) as a control. The
quantity of virus production was monitored by measuring CA-
p24 antigen in the culture supernatant every 12 h. The amounts
of CA-p24 detected in VSV-G pseudotyped virus and in control
were almost equal up to 24 h post-transfection. However, CA-
p24 production of the former became 10 times higher than that
of control at 36 h and finally 20 times higher at 48 h (Fig. 1A).
The actual amount of CA-p24 of virus from 3×106 of
transfected cells with pseudotyping was typically 20–40 μg in
total. This enhancement may have been caused by some
transactivation effects of VSV-G, or by retro-transduction of the
cells within the transfected cell culture, which then leads to
production of the progeny virus. The absence of the enhance-
ment at 12 or 24 h post-transfection suggests that transactivation
was unlikely since the transactivation effect should become
apparent from the onset of protein expression. In subsequent
experiments, we therefore examined the possibility of retro-
transduction of virus thus produced.
Retro-transduction of pseudotyped virus during transfection
The transfected cells were harvested 48 h post-transfection
and viral antigens within the cells were detected by westernFig. 1. Enhancement of virus production by pseudotyping. (A) Time course of HIV-1
cells along with either pCG-VSVG or pGEM-5Zf(+), and the quantity of virus pro
transfection by measuring CA-p24 antigen. The value for NLNh without pseudotypin
Error bars represent the mean standard error for the difference between experiments. (
transfection and lysed. Viral antigens within cell lysates were detected by western bl
except for the use of viral pol mutant pNLN-RI instead of the wild-type pNLNh.blotting (Fig. 1B). The viral antigens within cells producing the
env-lacking virus were mostly large, seemingly uncleaved, and
with the precursor protein Gag-Pr55 dominant. On the other
hand, the protein profile within the cells producing the VSV-G
pseudotyped virus was strikingly different. The majority of viral
antigens were mature proteins, such as CA-p24 and MA-p17,
while the number of immature proteins was very limited. This
observation was in agreement with a hypothesis that the viral
antigen within cells producing the pseudotyped virus mainly
came from mature virions, which would support the concept of
retro-transduction of the released virus.
To examine this possibility, a pol mutant pNLN-RI was
constructed from pNLNh. The mutant had a large deletion at the
RT and IN genes in addition to an Env frameshift, while the
expression of functional Env, RT, and IN was eliminated. The
VSV-G pseudotyped NLN-RI was therefore not able to
complete retro-transduction to produce its progeny. Next,
293T cells were co-transfected with pNLN-RI along with either
pCG-VSVG or pGEM-5Zf(+), and the quantity of virus
production was monitored by measuring CA-p24. No difference
in virus production was observed between VSV-G pseudotyped
and non-pseudotyped viruses during 48 h post-transfection (Fig.
1C). This indicates that the enhancement of virus production
was impaired by the elimination of RT expression and
subsequent inhibition of retro-transduction.production during transfection. The plasmid pNLNh was transfected into 293T
duction in the culture supernatant was monitored at 12, 24, 36, and 48 h post-
g at 12 h was set at 1. Results show the averages of three separate experiments.
B) Profiles of viral antigen in transfected cells. Cells were harvested at 48 h post-
otting using serum from HIV-1 infected patients. (C) Similar experiment as in A
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to retro-transduction
To further test our hypothesis, two more experiments were
performed. First, 293T cells were co-transfected with pNLNh
and pCG-VSVG in the presence or absence of viral enzyme
inhibitors. We used an effective RT inhibitor AZT (Mitsuya et
al., 1985) and a protease inhibitor Ritonavir (Markowitz et al.,
1995) (Fig. 2). For efficient functioning of AZT, the amount of
plasmid DNAs used in AZT experiment was reduced to 0.5 μg
in total, and the day after transfection, the medium was replaced
with fresh medium with or without the inhibitors. The amounts
of virus production were measured 48 h post-transfection.
When 0.5 μg of DNA was transfected into 3×106 cells, actual
amount of CA-p24 of pseudotyped virus was typically 1–2 μg.
Virion production was reduced to the same level as that ofFig. 2. Effect of viral enzyme inhibitor on enhancement. (A) 293T cells were co-
transfected with 0.25 μg of pNLNh and 0.25 μg of either pCG-VSVG or pGEM-
5Zf(+) in the absence or presence of 0.005, 0.05, 0.5, and 5 μMAZT. The virus
particles derived from the cells were collected at 48 h post-transfection, and CA-
p24 antigen was quantified. The value for NLNhwithout pseudotyping and AZT
was set at 1. Results show the averages of three separate experiments. Error bars
represent the mean standard error for the difference between experiments. (B)
293T cells were co-transfected with 2.5 μg of pNLNh and 2.5 μg of either pCG-
VSVG or pGEM-5Zf(+) in the absence or presence of 0.417 or 1.37 μM
Ritonavir. Western blotting of released virion was performed and viral antigen
was detected by anti-HIV-1 p24-CA monoclonal antibody. A series of dilution
controls was generated (not shown), and the amount of Pr55-Gag were
measured. The value for a sample with pseudotyping with 1.37 μM Ritonavir
was set at 1. The amount of CA-p24 in the samples was efficiently reduced by
the effect of Ritonavir. Results show the representative data of two independent
experiments with similar results.
Fig. 3. Effects of fusion-defective VSV-G or HIV-2 Env on enhancement.
pNLNh was transfected into 293T cells along with either pCG-VSVG, pCGVG-
G124E, pCGVG-P127D, pCGH2Env or pGEM-5Zf(+), and the virus in the
culture supernatant was monitored at 12, 24, 36, and 48 h post-transfection by
measuring CA-p24 antigen. The values for NLNh without pseudotyping at 12 h
was set at 1. (A) Effect of mutation lacking VSV-G fusion. Results show the
averages of three separate experiments. Error bars represent the mean standard
error of the difference between experiments. (B) Effect of HIV-2 Env
pseudotyping. Results show the representative data of two independent
experiments with similar results.control in the presence of 5 μM AZT, and the enhancement was
recovered as the concentration of the drug was reduced (Fig.
2A). The effect of Ritonavir was similar to that of AZT since
0.417 μM or more Ritonavir severely blocked the enhancement
of virion production measured by pr55-Gag amounts (Fig. 2B).
For the second experiment, two VSV-G fusion defective
mutants, pCGVG-G124E and pCGVG-P127D, were con-
structed. Both mutants contain one amino acid substitution at
the fusion domain of the protein and reportedly lose their
membrane fusion activity although their expression level at cell
surface remains similar to that of the wild-type (Fredericksen
and Whitt, 1995). The mutants were compared to the wild-type
VSV-G (WT-G) in terms of viral production enhancement by
pseudotyping (Fig. 3A). Both of the mutants showed very
similar effects. Unexpectedly, the amount of virus production
by the mutants was reduced throughout by approximately half
compared to that by the non-pseudotyped virus. Nonetheless,
the time course of virus production kinetics was almost identical
for the mutants-pseudotyped and non-pseudotyped virus and
drastically different from that of WT-G. Some of the data may
Fig. 4. GFP-virus transfection and viral DNA integration. 293T cells were co-
transfected with 0.25 μg of pMSMnG and 0.25 μg of either pCG-VSVG or
pGEM-5Zf(+) and were harvested at 12, 24, 48, 72, and 96 h post-transfection.
Half of each sample was fixed and subjected for FACS analysis, and total DNA
of latter half was extracted for Alu-PCR analysis. (A) GFP expression of
transfected cells. Percentages of GFP-positive cells per total cells were
indicated. (B) Alu-PCR analysis for integrated viral DNA quantification. The
value for the VSV-G(−) sample at 12 h was set at 1. Results show the
representative data of two independent experiments with similar results.
Fig. 5. VSV-G content and infectivity per viral antigen in early and late stages of
transfection. Virions derived from 293T cells co-transfected with pNLNh and
pCG-VSVGwere harvested at 24 and 48 h post-transfection, purified, and lysed.
CA-p24 antigen and VSV-G in the lysate were measured by ELISA and by
western blot, respectively. (A) Western blot of VSV-G on the virion. The time
the virion was harvested and the amount of CA-p24 antigen for each lane are
indicated. (B) VSV-G content per viral antigen. Signal intensities of VSV-G on
the membrane were quantified as described in Materials and methods. (C)
Infectivity of ‘early’ and ‘late’ virus. M8166/H1luc cells (106) were infected
with three serially diluted viruses. At 24 h post-infection, cells were lysed and
luciferase activity in the cell lysate was measured. The values for the virus at
24 h were set at 1. Results show the averages of at least three separate
experiments. Error bars represent the standard deviation between experiments.
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envelope. To verify this possibility, we tried pseudotyping of
envelope protein (Env) of HIV-2, which is a closely related
virus of HIV-1. As the CD4 antigen, the cell surface receptor for
HIV-1 and 2 (McClure et al., 1987), is not expressed on the
surface of non-lymphocyte cells such as 293T, virion
pseudotyped with HIV-2 Env is noninfectious to 293T cells.
The data of HIV-2 Env pseudotyping were very similar to that
of the fusion defective mutants of VSV-G (Fig. 3B), suggesting
that envelope suitability does not affect virion production. HIV-
2 Env pseudotyping was confirmed by infectivity assay. The
infectivity of it per viral antigen was comparable to that of VSV-
G pseudotyped one, suggesting that HIV-2 Env was efficiently
incorporated into HIV-1 virion (data not shown). These results
are a clear indication that the viral production enhancement by
VSV-G pseudotyping was completely eliminated by the
blocking of viral infectivity to producer cells and suggest thatthe enhancement was caused by retro-transduction and
subsequent replication of the virus.
The GFP virus experiment and detection of provirus
integration
To gain direct evidence of the retro-transduction, we
constructed pMSMnG, a derivative of pNL4-3 expressing the
green fluorescent protein (GFP) instead of viral nef protein. The
293T cells were transfected with 0.25 μg of pMSMnG along
with or without 0.25 μg of pCG-VSVG, and GFP expression
and viral DNA integration of the cells were analyzed from 12 h
to 96 or 72 h after transfection (Fig. 4). The amount of GFP-
positive cells was similar between with and without VSV-G
expression until 24 h. After that, that of VSV-G positive sample
was increased dramatically and reached nearly to 70% at 72 h
whereas that of VSV-G negative ones was only slightly
increased to 15% (Fig. 4A). Viral DNA integration was much
drastic. It was virtually not observed in VSV-G negative sample
throughout the experiment, whereas in VSV-G positive sample,
very large amount of viral DNA integration was detected later
than 24 h post-transfection (Fig. 4B). These data clearly
135M. Ohishi et al. / Virology 362 (2007) 131–138indicated the occurrence of massive retro-transduction and
subsequent progenitor production.
Reduction of viral infectivity by retro-transduction
Finally, we examined differences between ‘early’ and ‘late’
virus particles. The virion production of the WT-G pseudotyped
virus 48 h post-transfection was enhanced up to 20 times
compared to that of non-pseudotyped viruses, whereas no such
difference was observed at 24 h. This implies that most of the
pseudotyped viruses at 48 h can be assumed to have been the
result of replication, which might have resulted in some
characteristics different from those of the virion produced
solely by transfection. To verify this possibility, we harvested
the total virus at 24 h (‘early’) and 48 h (‘late’) post-transfection
and measured the amounts of virus production by CA-p24
ELISA and VSV-G on virus by western blotting (Fig. 5). When
we calculated the ratio of VSV-G to CA-p24 at the two time
points, we found that the VSV-G content of the ‘early’ virus was
approximately 5 times higher than that of the ‘late’ virus. This
indicates that, under certain conditions, the relative amount of
VSV-G of the ‘late’ virus is drastically reduced compared to that
of the ‘early’ virus particle. To determine the effect of this
reduction on virus infectivity, a single-round infection assay
using the M8166/H1luc reporter cell line (Nagao et al., 2004)
was performed (Fig. 5C). The actual value of infectivity of
‘early’ virus was typically 1.3×105 RLU/s CA-p24 μg. The
infectivity of the ‘early’ virus per CA-p24 was nearly 4 times
higher than that of the ‘late’ virus. This shows that the
infectivity of the ‘early’ and ‘late’ viruses mostly depends on the
amount of VSV-G per virion and therefore could alter
dramatically under certain conditions.
Discussion
Retrovirus pseudotyping is one of the most commonly used
methods for not only gene delivery, but also virological studies.
Since transfection of cells with envelope and gag/pol expression
vectors makes it easy to generate infectious particles, this
method rarely causes concern. However, notable incidents are
sometimes observed even in the case of common experiments.
In the study reported here, we focused on the enhancement of
HIV-1 production by VSV-G protein pseudotyping. In the first
set of experiments, we observed up to 20-fold enhancement of
viral production by VSV-G pseudotyping, with no enhancement
occurring on or before 24 h post-transfection (Fig. 1A). We
therefore hypothesized the occurrence of retro-transduction of
the virus produced and subsequent virion production. Altered
viral antigen profiles in transfected cells with or without
pseudotyping indicated the presence of mature viral proteins in
the cells with pseudotyping, thus corroborating our hypothesis
(Fig. 1B). The experiment using the HIV-1 pol mutant also
suggested a close correlation between enhancement and viral
infectivity (Fig. 1C). In the subsequent experiments, we
eliminated the infectivity of the produced virions by viral
enzyme inhibitors (Fig. 2), fusion defective mutation in VSV-G,
or HIV-2 Env (Fig. 3). Both of the experiments resulted in lossof the enhancement. These data all strongly suggested that the
retro-transduction of the produced virus by the transfectant
resulted in the release of large quantities of progeny virions.
The virus production was reduced in the virus pseudotyped
with VSV-G mutants and HIV-2 Env compared to that in control
from 12 h to 48 h post-transfection (Fig. 3). This was possibly
due to overexpression of the genes by the CAG promoter since
CAG promoter activity is very strong (Niwa et al., 1991) and
may take away the transcription/translation factors from other
promoters. Reduction of the viral protein was not observed in
case of WT-G pseudotyping, probably because the reduction of
viral expression offset the enhancement of viral production by
WT-G at 12 h, while the enhancement became dominant after
that.
The experiment using GFP-virus gained direct evidence for
retro-transduction (Fig. 4). From 24 h to 72 h post-transfection,
the percentage of GFP-positive cells just doubled in non-
pseudotyped sample, which might reflect the period required for
maturation of GFP in cells. In contrast, the increase was more
than eight times in VSV-G pseudotyped sample. The result of
Alu-PCR experiment gave us more solid evidence. The amount
of integrated viral DNA was rapidly increased after 24 h post-
transfection and reached more than 200-fold higher than the
background levels from 24 h to 72 h post-transfection (Fig. 4B).
As the viral DNA integration was not detected in non-
pseudotyped sample, this result directly demonstrated retro-
transduction by pseudotyping during transfection.
The final experiment produced a striking result in terms of
alteration of viral envelope incorporation and infectivity (Fig.
5). There was a more than 80% reduction in the quantity of
VSV-G per virus at 48 h post-transfection compared to that at
24 h. Moreover, the infectivity of the ‘late’ virus was reduced
in parallel to one-fourth that of the ‘early’ virus. Throughout
the experiments, we used the calcium phosphate method for
DNA transfection (Aldovini and Walker, 1990), which is very
popular due to its low cost, ease of manipulation, and
efficiency. Co-transfection of multiple vectors enables a cell
to uptake multiple genes simultaneously, and it is known that,
with this method, usually 10–50% of the cells take up the
DNA and express the genes thus introduced (Ausubel et al.,
1995). In our experiment, we usually noted a transfection
efficiency of 20% at most (data not shown). In other words, far
more than half the numbers of cells within a dish remained
untransfected. The VSV-G pseudotyped virus could equally
retro-transduce both transfected and untransfected cells during
a transfection experiment. The genome of the pseudotyped
virion lacked its original env gene and many of the cells were
untransfected and thus did not express VSV-G on their surface.
As a result, the majority of the cells probably produced
progeny virions without envelope proteins. This implies that
the reduction of VSV-G per virion observed represents a vast
increase in noninfectious particles and a relative decrease in
the ratio of pseudotyped virions. As this ratio can vary greatly
depending on the time and conditions during transfection,
infection experiments using such a mixture of infectious and
noninfectious viruses may sometimes produce inconsistent
results.
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compare the infectivity of mutants to that of the wild-type virus,
single-round replication assays of pseudotyped viruses are often
performed. If the infectivity of the mutants is reduced, which is
very likely, the quantity of noninfectious progeny virions from
cells retro-transducted by the mutants pseudotyped with VSV-G
would be reduced. As a result, the quantity of infectious virions
pseudotyped with the VSV-G contained in the mutants could be
much larger than that of the wild-type. In such a case, the
infectivity of the mutant per viral antigen would be greatly
overestimated and may produce a misleading interpretation of
the results.
Construction of a helper-vector system with self-inactivating
vector (Miyoshi et al., 1998) eliminates the possibility of
reproducing noninfectious viruses, and thus can solve the
problems concerned. Nonetheless, retro-transduction of the
vector is bound to occur as a result of VSV-G pseudotyping, and
retro-transduction of the vector by the vector producing cells
might yield somewhat unexpected results such as increase of
pseudo-transduction (Liu et al., 1996).
In conclusion, we have demonstrated that retro-transduction
of HIV-1 pseudotyped with VSV-G into 293T cells resulted in
the enhancement of virus production during transfection. The
quantity of infectious viruses pseudotyped by VSV-G to that of
the total quantity of viruses is significantly different depending
on whether or not the enhancement occurs. In a simple
experiment, such as making gene transfer vectors by VSV-G
pseudotyping, this issue should not matter much. However,
when the harvested virus is used for assays relating to
infectivity, there are certain problems that possibly cause
misleading of the results. Although VSV-G pseudotyping is
very easy and convenient, the conditions under which this
procedure is used should be carefully considered.
Materials and methods
Constructs
Replication-competent HIV-1 proviral clone pNL4-3 (Ada-
chi et al., 1986) was digested with NheI (position 7250), blunted
with KOD DNA polymerase, and self-ligated with T4 DNA
ligase for the construction of pNLNh. pNLNh thus carries a 4-
base insertion mutation within the env region, and Env protein
expression is abrogated. To construct pNLN-RI, the BalI
fragment encoding a part of the pol gene (position 2619 to
4551) was removed from pNLNh. EGFP gene was amplified
using pCMX-SAH/Y145F (Kallio et al., 1998) (a generous gift
from Dr. Takao Masuda, Tokyo medical and dental university)
as a template and primers (5′-GGATTTTGCTATAAGATGGT-
GAGCAAGGGCG-3′/5′-CTCGAGTTACTTGTACAGCTC-
3′), and a portion of the env gene of pNL4-3 was amplified
using primers (5′-GTGCTGTTAACTTGCTCAATGCC-3′/5′-
CGCCCTTGCTCACCATCTTATAGCAAAATCC-3′). Two
fragments were purified, mixed, and amplified again with the
second and third primers to generate a fragment including
EGFP utilizing ATG codon of nef gene as its own start codon
and obtaining XhoI site just downstream of its stop codon. Thefragment was cloned into pGEM-T Easy (Promega) and verified
its nucleotide sequence to make pGEMHnGX. The plasmid
pMSMBA (McBride and Panganiban, 1996), a derivative of
pNL4-3, was digested with HpaI and XhoI, and the HpaI–XhoI
fragment of pGEMHnGX including EGFP gene was inserted in
the corresponding position to construct pMSMnG.
pCGVG-G124E and pCGVG-P127D were generated by
replacing the 1123-bp XbaI–Acc65I fragment in pCG-VSVG (a
generous gift from Prof. Hideo Iba, Institute of Medical
Science, University of Tokyo) with the corresponding fragment
carrying the G124E and P127D mutation, respectively. The 5′
part of G124E and P127D fragments were amplified using
primer pairs 5′-GCTCTAGAGCCTCTGCTAAC-3′/5′-AGG-
GAACTCTGGATTCAGC-3′ and 5′-GCTCTAGAGCCTCT-
GCTAAC-3′/5′-TTTGATCAGGGAAGCCTG, respectively.
The 3′ part of the G124E and P127D fragments was amplified
using primers 5′-GCTGAATCCAGAGTTCCC-3′/5′-TAGGG-
TACCATTGATTATGGT-3 ′ and 5 ′ -CCAGGCTTC-
CCTGATCAAA-3′/5′-TAGGGTACCATTGATTATGGT-3′,
respectively. The total G124E fragment was amplified with
primers 5′-GCTCTAGAGCCTCTGCTAAC-3′/5′-TAGGG-
TACCATTGATTATGGT-3′ (underlined nucleotides represent
XbaI and Acc65I restriction sites) using the 5′ and 3′ parts of
G124E as templates. The total P127D fragment was amplified
in the same way as described above. The env coding region of
pGH123 (Shibata et al., 1990), a molecular infectious clone of
HIV-2, was amplified with primers (5′-GCCGCCATGTGTGG-
TAAGAGTCTAC-3′/5′-CTACAAGTCGTAACCATCGTC-
3′) to add kozak sequence at 5′ end. The amplified fragment
was cloned into pGEM-T Easy to generate pGEMH2env, and
the sequence was verified. The HIV-2 env expression vector
pCGH2env was generated by replacing an EcoRI fragment of
pCG-VSVG including whole VSV-G fragment with the EcoRI
fragment of pGEMH2env including the env gene.
Cell culturing and transfection
293T cells were maintained in Dulbecco's modified Eagle's
medium supplemented with 10% fetal calf serum, penicillin,
and streptomycin. The cells were transfected with the calcium
phosphate method (Aldovini and Walker, 1990) using either
pNLNh or pNLN-RI and either pGEM-5Zf(+), pCGH2env,
pCG-VSVG, or its derivatives.
Virus purification
At 24 or 48 h after transfection, the culture supernatants of
the transfected cells were centrifuged at 1570×g for 20 min at
4 °C, and virus particles in the supernatants were pelleted by
ultracentrifugation (151,000×g, 1 h) through a 20% sucrose
cushion. The pelleted viruses were then resuspended in
growth medium for infection experiment or lysed with lysis
buffer (50 mM Tris–HCl—pH 7.5, 100 mM NaCl, 10 mM
EDTA, 1% SDS) for western blotting or CA-p24 quantitation.
CA-p24 antigen was quantified with an ELISA kit (ZeptoMe-
trix Corp., Buffalo, NY) according to the manufacturer's
instructions.
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At 24 and 48 h post-transfection, the resultant virion was
purified and used for infection into M8166/H1luc cells (Nagao
et al., 2004), which contain integrated reporter DNA carrying
HIV-1 long terminal repeat (LTR) and luciferase. Upon
infection with HIV-1, HIV-1 LTR is activated along with the
expression of viral transactivator Tat, and luciferase expression
in cytoplasm is induced. For our study, the cells (1×106) were
infected at 37 °C with 300 μl of three serially diluted viruses.
After 90 min, the cells were washed with PBS, added to 1.5 ml
of media and cultured for 40 h at 37 °C. The infected cells
were then washed with PBS and lysed with 125 μl of Glo lysis
buffer (Promega), and a 50 μl sample of each lysate was
assayed for photon emission after the addition of 50 μl of
Bright-Glo Reagent (Promega) with a microplate luminometer
(Centro LB 960; Berthold Technologies, Bad Wildbad,
Germany).
Western blotting analysis
The lysates from the pelleted virus particles and cell lysates
were prepared as described previously (Willey et al., 1988),
while the proteins were resolved on SDS–4–12% polyacryla-
mide gels and then electrophoretically transferred to poly-
vinylidene difluoride membranes. ECL western blotting
detection reagents (Nakalai Tesque, Kyoto, Japan) were used
to detect VSV-G or HIV-1 antigen on the membranes. Briefly,
the membranes were incubated for 1 h at room temperature with
anti-VSV-G polyclonal antibody (Rockland Immunochemicals,
Gilbertsville, PA), the serum of HIV-1 infected patients, or anti-
HIV-1 CA-p24 monoclonal antibody (Advanced Biotechnolo-
gies Inc., Columbia, MD) and washed. They were then
incubated for another 1 h with horseradish peroxidase-
conjugated anti-rabbit or anti-human IgG (Vector Laboratories,
Burlingame, CA), washed, and visualized by chemilumines-
cence with LAS-1000 (Fujifilm, Tokyo, Japan) according to the
manufacturer's manual. The relative intensity of each band was
quantified by digital image analysis using ImageGauge software
(Fujifilm).
Cell cytometry analysis
The 293T cells were harvested, washed twice with PBS
(−), and fixed by suspending in 1% formaldehyde–PBS(−).
The fixed cells were analyzed by FACScan (Bekton
Dickinson, Franklin Lakes, NJ) to measure the expression
of GFP.
Genomic DNA preparation
Transfected cells were harvested at 12, 24, 48, and 72 h post-
transfection, washed twice with PBS(−), and pelleted. GenElute
mammalian genomic DNA miniprep kit (Sigma, St. Louis, MO)
was used to extract total DNA of the cells. DNA was digested
overnight with DpnI restriction enzyme at 37 °C to eliminate
contaminating plasmids which were methylated.Alu PCR analysis
For integrated proviral DNA quantitation, a modified Alu-
PCR method from a recent report (Brussel and Sonigo, 2003)
was employed. In the first round of PCR, two outward-facing
Alu primers that anneal within the conserved regions of the Alu
repeat element were used together with an HIV-1 LTR specific
primer (L-M667) to optimize the probability of amplifying an
LTR sequence since Alu elements could be present in either
orientation relative to the integrated provirus. L-M667 consisted
of an HIV-1 LTR-specific sequence fused with a lambda phage-
specific tag sequence at the 5′ end (Brussel and Sonigo, 2003).
For the second round of PCR (real-time PCR), a lambda-
specific primer (Lambda T) (Brussel and Sonigo, 2003) was
used as a sense primer to detect only the amplified fragments in
the first round of PCR, and a Taqman probe and an anti-sense
primer were selected from the set for R/U5 DNA detection in
the previous report (Julias et al., 2001). Cycling conditions of
the first round of PCR were 94 °C for 3 min followed by 22
cycles of 94 °C for 30 s, 66 °C for 30 s, 70 °C for 10 min, and
then 72 °C for 10 min (Ikeda et al., 2004). Equal volume of
DNA (0.15 μg) was applied for amplification. Ten-fold serially
diluted DNA samples of 72 h post-transfection with VSV-G
pseudotyping were employed as standards. Total amount of
DNA in each standard was adjusted by adding total DNA of
mock-transfected cells. The resultant PCR products were
diluted 100-fold and subjected to real-time PCR using
ABI7500 (Applied Biosystems, Foster City, CA).
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